Pyure designs and manufactures commercial air purifiers intended to provide dynamic protection against a range of pathogens while eliminating volatile organic compounds and odors. Its technology mimics the sanitizing effect of sunlight by safely generating hydroxyls and diffusing organic oxidants indoors. The company's flagship product is FDA-registered as a class II medical device and has been successfully tested for efficacy in reducing airborne SARS-CoV-2. Pyure markets its systems for commercial indoor air and surface sanitation to support safer resumption of pre-pandemic social and business interactions. The article notes the company is experiencing growth and continuing commercial traction, supported by external investment. PYURE designs and manufactures commercial air purifiers that provide dynamic protection against a range of pathogens and improve indoor air quality by eliminating volatile organic compounds and odors. Its proprietary technology mimics sunlight by safely generating hydroxyls and diffusing organic oxidants indoors. The company’s flagship product is FDA-registered as a Class II medical device, and PYURE was completing testing on SARS-CoV-2 at the time of the release. PYURE offers portable devices, in-duct units and HVAC-integrated solutions that can scale from individual offices and classrooms to entire buildings, treating from a few thousand to hundreds of thousands of square feet. Its solutions are used by multinational technology companies, public school boards and firms in the hospitality sector. PYURE is a private U.S. company located in Boynton Beach, Florida, and its leadership cites over 15 years of manufacturing expertise.

Total raised

$4M

Funding rounds

2

Latest round

Equity

Latest activity

Aug 2021